Condition: BRCA-Mutated Breast Carcinoma · HER2-negative Breast Cancer · Sponsor: Fudan University
This study is a prospective, open-label, multi-center, phase II clinical trial designed for HER2-negative breast cancer with pathogenic mutations in the germline gene (gBRCA1/2) that were indicated for neoadjuvant chemotherapy. The characteristics of this study are a precision treatment scheme without chemotherapy, the scheme of HRS-1167 combined with famitinib neoadjuvant therapy for patients with gBRCA mutations is explored, and the efficacy of combined immunotherapy is further explored according to the efficacy of the combination of the two drugs.
This description comes directly from the study's public registry record.
Zhi-Ming Shao, MD · 86-21-641755901105 · zhimingshao@yahoo.com
Xi-Yu Liu, MD · 86-21-64175590-63202 · liu-xiyu@163.com
Always discuss trial participation with your own doctor first.
| Breast cancer institute of Fudan University Cancer Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06516289